Skip to main content
Xbrane Biopharma logo

Xbrane Biopharma — Investor Relations & Filings

Ticker · XBRANE ISIN · SE0007789409 LEI · 5493008DKD05APTKQO39 ST Manufacturing
Open in API
Filings indexed 359 across all filing types
Latest filing 2023-05-22 Share Issue/Capital Cha…
Country SE Sweden
Listing ST XBRANE

About Xbrane Biopharma

https://xbrane.com/en/

Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.

Recent filings

Filing Released Lang Actions
Xbrane offentliggör avsikt att genomföra en riktad nyemission och en emission av konvertibla obligationer om totalt cirka 325 miljoner kronor i finansiering
Share Issue/Capital Change Classification · 99% confidence The document is a press release from Xbrane Biopharma AB announcing its intention to raise capital through a directed new share issue (nyemission) and an issuance of convertible bonds. This action directly relates to the company's financing activities and capital structure changes. The key terms are 'riktad nyemission' (directed new issue), 'emission av konvertibla obligationer' (issuance of convertible bonds), and 'finansiering' (financing). This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it also mentions preliminary Q1 2023 revenues, the primary focus and headline announcement concern the capital raise.
2023-05-22 Swedish
Announcement from Xbrane Biopharma's annual general meeting
AGM Information Classification · 100% confidence The document explicitly states it is an "Announcement from Xbrane Biopharma's annual general meeting" and details the resolutions passed at the AGM held on May 4, 2023. Key topics covered include the adoption of financial statements, allocation of profit, election of the board and auditor, approval of remuneration, and amendments related to incentive programs (LTIP 2022 and LTIP 2023). These are all typical items discussed and voted upon during an Annual General Meeting. Therefore, the classification is AGM-R (AGM Information).
2023-05-04 English
Kommuniké från årsstämman i Xbrane Biopharma
AGM Information Classification · 100% confidence The document is explicitly titled "Kommuniké från årsstämman i Xbrane Biopharma" (Communiqué from the Annual General Meeting in Xbrane Biopharma) and details the decisions made during the meeting held on May 4, 2023. Key decisions include the approval of financial statements, dividend disposition, election of the board and auditor, changes to incentive programs (LTIP 2022 and LTIP 2023), and authorization for future share issues. These contents are characteristic of the official minutes or summary released following an Annual General Meeting (AGM). Therefore, the correct classification is AGM-R.
2023-05-04 Swedish
STADA och Xbrane levererar Ximluci® (ranibizumab) i England under kontrakt med NHS
Regulatory Filings Classification · 95% confidence The document is a press release announcing that STADA and Xbrane have won a framework agreement to supply Ximluci® (ranibizumab biosimilar) to the NHS in England. It details the contract value, the product, and the partnership. The final line explicitly states: "Denna information är sådan information som Xbrane Biopharma är skyldigt att offentliggöra enligt EU: s marknadsmissbruksförordning." (This information is information that Xbrane Biopharma is obliged to disclose pursuant to the EU's Market Abuse Regulation.) This structure—a formal announcement of material information required by market regulations, often including contact details for media and investors, and referencing regulatory obligations—is characteristic of a general regulatory announcement or press release that doesn't fit a specific financial report type (like 10-K, IR, or ER). Since it is a formal disclosure mandated by market rules and doesn't fit the more specific categories (like Director's Dealing, Dividend Notice, or Earnings Release), the most appropriate fallback category is Regulatory Filings (RNS). The document length (6725 chars) is substantial enough that it is not merely an announcement *about* a report (RPA), but the report/announcement itself.
2023-04-25 Swedish
STADA and Xbrane supply Ximluci® (ranibizumab) in England under NHS contract
Regulatory Filings Classification · 98% confidence The document announces a commercial agreement between STADA and Xbrane regarding the supply of Ximluci® under an NHS Framework Agreement in England. It details the partnership, product information, market context, and financial implications (contract value). The final line explicitly states: "This information is information that Xbrane Biopharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication...". This structure, combined with the content focusing on a significant business development (contract award/supply agreement), strongly suggests a mandatory regulatory disclosure. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific insider transaction (DIRS), the most appropriate general category for a significant, mandatory, non-standard announcement under EU regulation is Regulatory Filings (RNS). It is not a Report Publication Announcement (RPA) because it is the substance of the announcement itself, not just a notice that a report is attached.
2023-04-25 English
XBRANE submits BLA for ranibizumab biosimilar candidate to FDA
Report Publication Announcement Classification · 95% confidence The document is a short announcement from Xbrane Biopharma AB regarding the submission of a Biologics License Application (BLA) to the FDA for a biosimilar candidate. It contains key updates, contact information, and a concluding statement about being obliged to make the information public pursuant to the EU Market Abuse Regulation. Crucially, it includes an 'Attachments' section with a link to a PDF document, and the total document length is very short (2452 characters). According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of information or attaching a report is classified as a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Since this is a specific regulatory/corporate update that doesn't fit the other specific categories (like DIV, DIRS, or ER), and it functions as an announcement of a corporate action/filing, RPA is the most appropriate fit, as it announces the submission/publication of a major regulatory step. If RPA were not available, RNS would be the fallback, but RPA specifically covers the announcement of publication/filing events.
2023-04-24 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.